Related resources
Full-text held externally
- PMID: 20716225
- UKPMCID: 20716225
- DOI: 10.1111/j.1365-2133.2010.09986.x
Search for item elsewhere
University researcher(s)
Academic department(s)
Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre.
Warren, R B; Brown, B C; Lavery, D; Griffiths, C E M
The British journal of dermatology. 2010;163(4):859-62.
Access to files
Full-text and supplementary files are not available from Manchester eScholar. Full-text is available externally using the following links:
Full-text held externally
- PMID: 20716225
- UKPMCID: 20716225
- DOI: 10.1111/j.1365-2133.2010.09986.x
Abstract
BACKGROUND: There are few reports of the practical use of adalimumab outside of a clinical trial setting and, to our knowledge, none from the U.K. OBJECTIVES: We assessed the efficacy and safety of adalimumab in a cohort of patients with severe psoriasis attending a tertiary dermatology referral centre in the U.K. METHODS: A retrospective case-note review was used to identify all patients initiated on adalimumab for psoriasis. RESI;TS: Baseline Psoriasis Area and Severity Index (PASI) was 24+/-11 (range 9-54; n=46). After 4 months' treatment with adalimumab 64% (29/45), of patients had achieved PASI 75 (75% decrease from baseline) whilst 80% (36/45) of patients met NICE criteria for continuation of treatment. Therapy was well-tolerated. Importantly, 68% (21/31) of patients who had previously received another tumour necrosis factor alpha inhibitor met NICE criteria for continuation of treatment at 16 weeks. CONCLUSIONS: In a cohort of U.K. patients with severe psoriasis, adalimumab has proved to be a significant addition to the expanding armamentarium of biologics for psoriasis. Pharmacovigilance, in the form of registries, is essential to assess the long-term safety of such drugs.